AI-Assisted Diagnosis for Stomach Problems
(AI-OD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method of using artificial intelligence (AI) during colonoscopies to diagnose small growths in the colon, known as polyps. The researchers aim to determine if AI can accurately identify these polyps, either independently or with a doctor's assistance, compared to standard methods. The trial also examines how well the AI's findings align with those of expert doctors and whether using AI can reduce costs for medical tests. Suitable candidates for this trial include individuals scheduled for an outpatient colonoscopy at the Centre Hospitalier de l'Université de Montréal, excluding those with conditions like active colitis or certain genetic syndromes. As an unphased trial, this study provides a unique opportunity to contribute to cutting-edge research that could enhance colonoscopy procedures for future patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
What prior data suggests that this AI-assisted diagnosis method is safe for use in colonoscopy procedures?
Research has shown that using artificial intelligence (AI) to help find polyps during colonoscopies is generally safe and well-received. Studies indicate that AI predicts the type of polyps, assisting doctors in deciding whether to remove them.
When AI is used alongside an endoscopist, studies have found that this combination improves accuracy without adding extra risk to patients. The endoscopist, an expert in examining the digestive system, provides an additional layer of safety.
In cases where AI operates independently during the procedure, research indicates that this method is also safe and provides results as accurate as traditional methods.
Both approaches have been tested for accuracy and effectiveness in real-time situations. These studies suggest that AI-assisted systems are as safe as regular diagnostic procedures.12345Why are researchers excited about this trial?
Researchers are excited about AI-assisted classification for stomach problems because it has the potential to enhance the accuracy and efficiency of diagnosing diminutive colorectal polyps during colonoscopy procedures. Unlike traditional methods that rely solely on an endoscopist's judgment, this approach leverages the CAD-eye detection and classification system, which can work with or without the endoscopist's input. This dual approach not only aims to improve diagnostic precision but also helps in streamlining the procedure, potentially leading to quicker diagnoses and better patient outcomes. By utilizing advanced AI technology, this method could significantly reduce the chances of missing serrated polyps, offering a promising improvement over existing diagnostic practices.
What evidence suggests that AI-assisted diagnosis is effective for stomach problems?
Studies have shown that using AI during a colonoscopy can help find more small growths in the colon, called polyps, compared to traditional methods. One study found that AI accurately and safely identified these small polyps. However, some research suggests that AI might not always excel at detecting very tiny polyps that could become cancerous. In this trial, participants will be assigned to one of two arms: one where the AI collaborates with a doctor's input using a system called CADx, and another where the AI operates autonomously. This system might also reduce costs by decreasing the need for lab tests on these polyps.46789
Who Is on the Research Team?
Daniel von Renteln, MD
Principal Investigator
Centre hospitalier de l'Université de Montréal (CHUM)
Are You a Good Fit for This Trial?
This trial is for people aged 45-80 who are having an outpatient colonoscopy at the Centre Hospitalier de l'Université de Montréal. They must understand and agree to the study by signing a consent form. It's not for those with severe health risks (ASA status >3), inflammatory bowel diseases, active colitis, blood clotting disorders, or inherited colorectal cancer syndromes.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo standard colonoscopy procedures with AI-assisted optical diagnosis for diminutive colorectal polyps
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Artificial intelligence-assisted classification (CADx)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Daniel Von Renteln
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor